Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD

Table 2 Transition probabilities based on logit model

CGI-S health states	CGI-S health states in Subsequent Week
CGI-S health states	Normal	Mild	Moderate	Severe
Stimulants only (mean SE)
Normal	0.759 (0.056)	0.238 (0.055)	0.003 (0.001)	0.000 (0.000)
Mild	0.081 (0.013)	0.826 (0.017)	0.093 (0.014)	0.000 (0.000)
Moderate	0.002 (0.001)	0.192 (0.015)	0.801 (0.015)	0.004 (0.003)
Severe	0.000 (0.000)	0.000 (0.000)	0.236 (0.068)	0.763 (0.068)
Combined GXR + stimulants (mean SE)
Normal	0.766 (0.041)	0.231 (0.041)	0.003 (0.001)	0.000 (0.000)
Mild	0.112 (0.014)	0.817 (0.016)	0.070 (0.011)	0.000 (0.000)
Moderate	0.003 (0.001)	0.258 (0.019)	0.737 (0.019)	0.003 (0.001)
Severe	0.000 (0.000)	0.000 (0.000)	0.361 (0.102)	0.550 (0.102)

CGI-S Clinical Global Impression-Severity, GXR guanfacine extended release, SE standard error

ISSN: 1471-244X